Results 121 to 130 of about 124,601 (306)

Diffuse Large B Cell Lymphoma of the Foot in a Patient with Rheumatoid Arthritis

, 2015
Patients with rheumatoid arthritis (RA) have an increased risk of developing malignant lymphomas, especially non-Hodgkin’s lymphoma (NHL). However, primary lymphoma in a joint is rare.
Madeleine Sampson, Anna Litwic, Elaine Dennison, Vipul Foria   +3 more
core  

Specific expression of miR-17-5p and miR-127 in testicular and central nervous system diffuse large B-cell lymphoma

, 2009
Recent studies have shown that certain non-coding short RNAs, called miRNAs, play an important role in diffuse large B-cell lymphomas. Patients with diffuse large B-cell lymphoma have great diversity in both clinical characteristics, site of presentation
van den Berg, Anke, Marije Booman, Stefano Rosati, Blokzijl, Tjasso, Kluin, Philip, Robertus, Jan-Lukas, Jan-Lukas Robertus, Schuuring, Ed, Tjasso Blokzijl, Anke van den Berg, Schuuring, Ed; id_orcid, Rosati, Stefano, Harms, Geert, Philip Kluin, van den Berg, Anke; id_orcid, Geert Harms, Ed Schuuring, van Imhoff, Gustaaf, Gustaaf van Imhoff, Daphne de Jong, de Jong, Daphne, Booman, Marije   +21 more
core   +1 more source

Refractory diffuse large B-cell Lymphoma

Journal of Taibah University Medical Sciences, 2023
Hajar Masrour, Latifa Lerhrib, Sanaa Bouchnafati, Widad Rhandour, Mounia Bouzayd, Laila Abarkan, Anas Oudrhiri, Nabil Al Saddiq, Rim Hanini, Yassine Chekkori, Falah Eddine Tohir, Ouazzani, Naoual Oubelkacem, Noufissa Alami Drideb, Zineb Khammar, Rhizlane Berrady   +15 more
doaj   +1 more source

Treatment of Diffuse Large B Cell Lymphoma

The Korean Journal of Internal Medicine, 2012
Diffuse large B cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma in all countries and all age groups. DLBCL is potentially curable, and the outcome of patients with DLBCL has completely changed with the introduction of therapy involving the monoclonal antibody rituximab in combination with chemotherapy.
openaire   +2 more sources

Case of primary diffuse large B-cell lymphoma of lacrimal sac in a Japanese patient

, 2010
Fusae Kajita1, Toshiyuki Oshitari1, Jiro Yotsukura1, Kaoru Asanagi1, Takayuki Baba1, Takashi Kishimoto2, Shuichi Yamamoto11Department of Ophthalmology and Visual Science, 2Department of Molecular Pathology, Chiba University Graduate School of Medicine ...
Jiro Yotsukura, et al, Fusae Kajita, Toshiyuki Oshitari   +3 more
core  

The Growth Supporting Role of ZDHHC11 Is Linked to the MEF2B–BCL6 Regulatory Circuit in Burkitt Lymphoma

International Journal of Cancer, EarlyView.
MEF2B and BCL6 have established functions in germinal center B‐cell biology and lymphomagenesis. The mechanism of MEF2B deregulation and its significance for cell survival in Burkitt lymphoma however remain unclear. This study highlights MEF2B as a crucial transcription factor in Burkitt lymphoma and suggests ZDHHC11 as an upstream regulator of MEF2B ...
Lotteke J. Y. M. Ziel‐Swier, Karolina Rassek, Yichen Liu, Annika Seitz, Jasper Koerts, Debora de Jong, Bea Rutgers, Anastasiia Kompaniiets, Julia Przybył, Martine E. D. Chamuleau, Anke van den Berg, Agnieszka Dzikiewicz‐Krawczyk, Joost Kluiver   +12 more
wiley   +1 more source

Efficacy and Safety Profile of a Rituximab, Methotrexate, and Thiotepa‐Based Regimen in Newly Diagnosed Primary CNS Lymphoma

International Journal of Cancer, EarlyView.
Primary central nervous system diffuse large B‐cell lymphoma (PCNS‐DLBCL) lacks an optimal first‐line induction strategy, particularly for older patients and those ineligible for intensive consolidation. In this retrospective cohort of 36 newly diagnosed patients, the rituximab + methotrexate + thiotepa (RMT) regimen as first‐line induction achieved ...
Haotian Wang, Jia Li, Luming Cao, Ying Zhang, Xin Wan, Xingtong Wang, Yangzhi Zhao, Zhaoxia Li, Chengqian Chen, Yang Song, Ou Bai   +10 more
wiley   +1 more source

Large cell lymphoma : correlation of HIV status and prognosis with differentiation profiles assessed by immunophenotyping

, 2011
Includes abstract.Includes bibliographical references (leaves 80-93).The study aimed to contribute a South African perspective by correlating the HIV status and prognosis of DLBCL and PBL with differentiation profiles assessed by ...
Pather, Sugeshnee
core  

Combination of Lenvatinib and Antibiotics: A Potential Approach to Enhance Sensitivity in Differentiated Thyroid Cancer

International Journal of Cancer, EarlyView.
Although lenvatinib is the current first‐line therapy for radioiodine‐refractory differentiated thyroid carcinoma, its use is limited by severe side effects and reduced sensitivity. Here, the authors assessed the potential of sensitizing differentiated thyroid carcinoma tumor cells with limited lenvatinib responsiveness through the administration of ...
Celina Ablinger, Petra Huber‐Cantonati, Daniela D. Weber, Sarah Pichler, Georg Schischkow, Marta Garcia‐Miralles, Christian Pirich, Gundula Rendl, Teresa Kiener, Thomas Felder, Martin Geroldinger, Robert Terkola, Barbara Kofler, Johanna Pachmayr   +13 more
wiley   +1 more source

Review of Diffuse large B cell lymphoma, pharmacological aspects of treatment and comparison of outcome between Pre-,Post Rituximab era

, 2017
Diffuse large B Cell lymphoma (DLBCL) is a type aggressive non-Hodgkin Lymphoma (NHL). About 30% of patients who diagnosed NHL is DLBCL in both male and female. It is divided into 3 major types which distinct by immunological characteristics.
Kim, Gang Kyu
core